News and Updates
QART MEDICAL – FDA Registration
QART Medical is excited to announce a major milestone for our company: We have registered our flagship product, the Q300™ with the United States Food and Drug Administration (FDA). The Q300™ system empowers embryologists to make objective, quantitative, recorded, and highly-informed decisions about the sperm cells that they intend to select for injection into oocytes during the most prevalent IVF procedure, ICSI (intra cytoplasmic sperm injection).
Read moreQART Medical – Presentation at the JSRM 2022 Conference
QART Medical presented at the 67th Annual Meeting of the Japan Society for Reproductive Medicine, on November 3-4th, 2022 (see: http://www.jsrm.or.jp/en/meetings_sch.html).
The conference took place in the Pacifico Yokohama Conference Center, Tokyo, Japan. The QART team showcased the Q300™ system, which empowers embryologists to make objective, quantitative, recorded, and highly-informed decisions about the sperm cells they select for injection into oocytes during IVF. The QART team was joined by our partners at Chartered Investment Managers who provided excellent in-country support. QART’s groundbreaking technology and the Q300™ system, were presented to embryologists, reproductive-medicine research scientists, hospital administrators and medical device distributors.
QART Medical, a Male Fertility Company, Discloses Recent Financing
October 20th, Raanana, Israel – The round was led by Chartered Group, an SEA-based investment management fund and included Hamamatsu Photonics and angel investors.
Read moreQART-Medical receives ISO13485 certificate
QART Medical is a MedTech startup, focusing on male fertility utilizing cutting edge bio-photonics technologies, originating from a decade’s work of Prof. Natan T. Shaked’s group in Tel-Aviv University.
Read moreQART Medical Ltd. has received ethical committee approvals
QART Medical Ltd. has received ethical committee approvals to commence clinical studies in medical centres in Israel. QART Medical is an MedTech start-up, addressing the huge unmet need of male infertility.
Read moreQart Medical Ltd. receives Seal of Excellence from EU Horizon 2020
Read moreQART Medical Ltd. has won the 3rd (monetary) prize in the 2020 from QCII
QART Medical Ltd. has won the 3rd (monetary) prize in the 2020 Qingdao High-tech Zone Lanebest International Innovation and Entrepreneurship Competition.
Read moreQART receives second grant support from the Israeli Innovation Authority
QART’s R&D efforts are focused at bringing to IVF clinics worldwide a novel system called QISITM (Quantitative Interferometric Sperm Imager) – allowing the embryologist to make highly informed decisions, when selecting individual sperm cells for injection into the (female) egg in a dish, in a procedure called ICSI (intra-cytoplasmic sperm injection).
Read moreQART Medical completes follow-on investment round
Raanana, Israel, September 2020; QART Medical completes follow-on investment round, led by Chartered Opus and joined by other existing, as well as new investors. Company was established to utilize advanced bio-photonics, to significantly improve the outcomes of ICSI (intra cytoplasmic sperm injection) treatments, a common type of IVF (in vitro fertilization) procedure, in which a single sperm cell is selected and manually injected into the female oocyte (i.e. egg).
Read more